메뉴 건너뛰기




Volumn 16, Issue 3, 2015, Pages 347-356

Ongoing challenges for pharmacotherapy for dyslipidemia

Author keywords

Atherosclerosis; Cardiovascular risk; Lipid modifying therapy; Lipids

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

EID: 84921442072     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.986094     Document Type: Review
Times cited : (6)

References (108)
  • 1
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 2
    • 77956960932 scopus 로고    scopus 로고
    • 30-year trends in serum lipids among United States adults: Results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006
    • Cohen JD, Cziraky MJ, Cai Q, et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol 2010;106:969-75
    • (2010) Am J Cardiol , vol.106 , pp. 969-975
    • Cohen, J.D.1    Cziraky, M.J.2    Cai, Q.3
  • 3
    • 84883777708 scopus 로고    scopus 로고
    • Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience
    • Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166:597-603
    • (2013) Am Heart J , vol.166 , pp. 597-603
    • Mampuya, W.M.1    Frid, D.2    Rocco, M.3
  • 4
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
    • Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
    • (2005) JAMA , vol.294 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3
  • 5
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • LaRosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 6
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
    • Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3
  • 7
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 8
    • 0037164314 scopus 로고    scopus 로고
    • PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
    • Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
    • (2002) Lancet , vol.360 , pp. 1623-1630
    • Shepherd, J.1    Blauw, G.J.2    Murphy, M.B.3
  • 9
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;35:1495-504
    • (2004) N Engl J Med , vol.35 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 10
    • 24644489081 scopus 로고    scopus 로고
    • Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada
    • Austin PC, Mamdani MM. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation 2005;112:1296-300
    • (2005) Circulation , vol.112 , pp. 1296-1300
    • Austin, P.C.1    Mamdani, M.M.2
  • 11
    • 26444618613 scopus 로고    scopus 로고
    • Trends in serum lipids and lipoproteins of adults, 1960-2002
    • Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-81
    • (2005) JAMA , vol.294 , pp. 1773-1781
    • Carroll, M.D.1    Lacher, D.A.2    Sorlie, P.D.3
  • 12
    • 84902576469 scopus 로고    scopus 로고
    • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2889-2934
    • Stone, N.J.1    Robinson, J.2    Lichtenstein, A.H.3
  • 13
    • 79960539641 scopus 로고    scopus 로고
    • ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
    • European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, Catapano AL, De Backer G, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
    • (2011) Eur Heart J , vol.32 , pp. 1769-1818
    • European Association for Cardiovascular Prevention and Rehabilitation1    Reiner, Z.2    Catapano, A.L.3    De Backer, G.4
  • 14
    • 61849110301 scopus 로고    scopus 로고
    • Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women
    • Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-9
    • (2009) Circulation , vol.119 , pp. 931-939
    • Mora, S.1    Otvos, J.D.2    Rifai, N.3
  • 15
    • 33846639147 scopus 로고    scopus 로고
    • Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study
    • El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;49:547-53
    • (2007) J Am Coll Cardiol , vol.49 , pp. 547-553
    • El Harchaoui, K.1    Van Der Steeg, W.A.2    Stroes, E.S.3
  • 16
    • 33645741889 scopus 로고    scopus 로고
    • Low-density lipoprotein and highdensity lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
    • Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and highdensity lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63
    • (2006) Circulation , vol.113 , pp. 1556-1563
    • Otvos, J.D.1    Collins, D.2    Freedman, D.S.3
  • 17
    • 33846637379 scopus 로고    scopus 로고
    • Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies
    • Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8
    • (2007) Circulation , vol.115 , pp. 450-458
    • Sarwar, N.1    Danesh, J.2    Eiriksdottir, G.3
  • 18
    • 38949171001 scopus 로고    scopus 로고
    • Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
    • Miller M, Cannon CP, Murphy SA, et al. PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
    • (2008) J Am Coll Cardiol , vol.51 , pp. 724-730
    • Miller, M.1    Cannon, C.P.2    Murphy, S.A.3
  • 19
    • 67651210632 scopus 로고    scopus 로고
    • Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
    • Emerging Risk Factors Collaboration. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23
    • (2009) JAMA , vol.302 , pp. 412-423
    • Erqou, S.1    Kaptoge, S.2    Perry, P.L.3
  • 20
    • 0033535977 scopus 로고    scopus 로고
    • Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease
    • Kugiyama K, Doi H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999;99:2858-60
    • (1999) Circulation , vol.99 , pp. 2858-2860
    • Kugiyama, K.1    Doi, H.2    Takazoe, K.3
  • 21
    • 0024501678 scopus 로고
    • High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
    • Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
    • (1989) Circulation , vol.79 , pp. 8-15
    • Gordon, D.J.1    Probstfield, J.L.2    Garrison, R.J.3
  • 22
    • 0024449985 scopus 로고
    • High-density lipoprotein - The clinical implications of recent studies
    • Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-16
    • (1989) N Engl J Med , vol.321 , pp. 1311-1316
    • Gordon, D.J.1    Rifkind, B.M.2
  • 23
    • 0017384270 scopus 로고
    • High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
    • Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
    • (1977) Am J Med , vol.62 , pp. 707-714
    • Gordon, T.1    Castelli, W.P.2    Hjortland, M.C.3
  • 24
    • 34748887666 scopus 로고    scopus 로고
    • HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    • Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
    • (2007) N Engl J Med , vol.357 , pp. 1301-1310
    • Barter, P.1    Gotto, A.M.2    LaRosa, J.C.3
  • 25
    • 36348975228 scopus 로고    scopus 로고
    • Effects of torcetrapib in patients at high risk for coronary events
    • Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
    • (2007) N Engl J Med , vol.357 , pp. 2109-2122
    • Barter, P.J.1    Caulfield, M.2    Eriksson, M.3
  • 26
    • 84870045994 scopus 로고    scopus 로고
    • Effects of dalcetrapib in patients with a recent acute coronary syndrome
    • Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99
    • (2012) N Engl J Med , vol.367 , pp. 2089-2099
    • Schwartz, G.G.1    Olsson, A.G.2    Abt, M.3
  • 27
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • Boden, W.E.1    Probstfield, J.L.2    Anderson, T.3
  • 28
    • 84904252744 scopus 로고    scopus 로고
    • Effects of extended-release niacin with laropiprant in high-risk patients
    • HPS2-THRIVE Collaborative Group. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12
    • (2014) N Engl J Med , vol.371 , pp. 203-212
    • Landray, M.J.1    Haynes, R.2    Hopewell, J.C.3
  • 29
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;35:1495-504
    • (2004) N Engl J Med , vol.35 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 30
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
    • Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
    • (2005) JAMA , vol.294 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3
  • 31
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • LaRosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 32
    • 33645524176 scopus 로고    scopus 로고
    • Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial
    • Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65
    • (2006) JAMA , vol.295 , pp. 1556-1565
    • Nissen, S.E.1    Nicholls, S.J.2    Sipahi, I.3
  • 33
    • 82555168428 scopus 로고    scopus 로고
    • Effect of two intensive statin regimens on progression of coronary disease
    • Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-87
    • (2011) N Engl J Med , vol.365 , pp. 2078-2087
    • Nicholls, S.J.1    Ballantyne, C.M.2    Barter, P.J.3
  • 34
    • 84888646672 scopus 로고    scopus 로고
    • C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy
    • Puri R, Nissen SE, Libby P, et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013;128:2395-403
    • (2013) Circulation , vol.128 , pp. 2395-2403
    • Puri, R.1    Nissen, S.E.2    Libby, P.3
  • 35
    • 29244483080 scopus 로고    scopus 로고
    • Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients
    • Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61-7
    • (2006) Am J Cardiol , vol.97 , pp. 61-67
    • Newman, C.1    Tsai, J.2    Szarek, M.3
  • 36
    • 84891804222 scopus 로고    scopus 로고
    • Intolerance to statins: Mechanisms and management
    • Bitzur R, Cohen H, Kamari Y, et al. Intolerance to statins: mechanisms and management. Diabetes Care 2013;36(Suppl 2):S325-30
    • (2013) Diabetes Care , vol.36 , pp. S325-S330
    • Bitzur, R.1    Cohen, H.2    Kamari, Y.3
  • 37
    • 84875728653 scopus 로고    scopus 로고
    • Statin discontinuation and intolerance: The challenge of lifelong therapy
    • Grundy SM. Statin discontinuation and intolerance: the challenge of lifelong therapy. Ann Intern Med 2013;158:562-3
    • (2013) Ann Intern Med , vol.158 , pp. 562-563
    • Grundy, S.M.1
  • 38
    • 84921513738 scopus 로고    scopus 로고
    • Statin treatment non-adherence and discontinuation: Clinical implications and potential solutions
    • Phan K, Gomez YH, Elbaz L, et al. Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. Curr Pharm Des 2014;20(40):6314-24
    • (2014) Curr Pharm des , vol.20 , Issue.40 , pp. 6314-6324
    • Phan, K.1    Gomez, Y.H.2    Elbaz, L.3
  • 39
    • 79959428660 scopus 로고    scopus 로고
    • Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis
    • Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64
    • (2011) JAMA , vol.305 , pp. 2556-2564
    • Preiss, D.1    Seshasai, S.R.2    Welsh, P.3
  • 40
    • 84901704225 scopus 로고    scopus 로고
    • Higher potency statins and the risk of new diabetes: Multicentre, observational study of administrative databases
    • Dormuth CR, Filion KB, Paterson JM, et al. Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014;348:g3244
    • (2014) BMJ , vol.348 , pp. g3244
    • Dormuth, C.R.1    Filion, K.B.2    Paterson, J.M.3
  • 41
    • 84866732882 scopus 로고    scopus 로고
    • Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence
    • Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol 2012;6:413-26
    • (2012) J Clin Lipidol , vol.6 , pp. 413-426
    • Maki, K.C.1    Bays, H.E.2    Dicklin, M.R.3
  • 42
    • 0026710526 scopus 로고
    • Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
    • Koskinen P, Mänttäri M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5
    • (1992) Diabetes Care , vol.15 , pp. 820-825
    • Koskinen, P.1    Mänttäri, M.2    Manninen, V.3
  • 43
    • 0037049366 scopus 로고    scopus 로고
    • Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)
    • Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604
    • (2002) Arch Intern Med , vol.162 , pp. 2597-2604
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3
  • 44
    • 70349334010 scopus 로고    scopus 로고
    • Myopathy with statin-fibrate combination therapy: Clinical considerations
    • Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009;5:507-18
    • (2009) Nat Rev Endocrinol , vol.5 , pp. 507-518
    • Jacobson, T.A.1
  • 45
    • 28044452217 scopus 로고    scopus 로고
    • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
    • Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
    • (2005) Lancet , vol.366 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 46
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
    • (2010) N Engl J Med , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 47
    • 36049001784 scopus 로고    scopus 로고
    • Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial
    • Keech AC, Mitchell P, Summanen PA, et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97
    • (2007) Lancet , vol.370 , pp. 1687-1697
    • Keech, A.C.1    Mitchell, P.2    Summanen, P.A.3
  • 48
    • 65649142619 scopus 로고    scopus 로고
    • Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial
    • Rajamani K, Colman PG, Li LP, et al. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-8
    • (2009) Lancet , vol.373 , pp. 1780-1788
    • Rajamani, K.1    Colman, P.G.2    Li, L.P.3
  • 49
    • 79960700766 scopus 로고    scopus 로고
    • Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
    • Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011;217:492-8
    • (2011) Atherosclerosis , vol.217 , pp. 492-498
    • Lee, M.1    Saver, J.L.2    Towfighi, A.3
  • 50
    • 77952708442 scopus 로고    scopus 로고
    • Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis
    • Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
    • (2010) Lancet , vol.375 , pp. 1875-1884
    • Jun, M.1    Foote, C.2    Lv, J.3
  • 51
    • 33947728699 scopus 로고    scopus 로고
    • Effects of a potent and selective PPARalpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: Two randomized controlled trials
    • Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPARalpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007;297:1362-73
    • (2007) JAMA , vol.297 , pp. 1362-1373
    • Nissen, S.E.1    Nicholls, S.J.2    Wolski, K.3
  • 52
    • 84898614282 scopus 로고    scopus 로고
    • Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: The AleCardio randomized clinical trial
    • Lincoff AM, Tardif JC, Schwartz GG, et al. AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014;311:1515-25
    • (2014) JAMA , vol.311 , pp. 1515-1525
    • Lincoff, A.M.1    Tardif, J.C.2    Schwartz, G.G.3
  • 54
    • 77952397461 scopus 로고    scopus 로고
    • Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    • Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-61
    • (2010) Atherosclerosis , vol.210 , pp. 353-361
    • Bruckert, E.1    Labreuche, J.2    Amarenco, P.3
  • 55
    • 70350516769 scopus 로고    scopus 로고
    • Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study
    • Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94
    • (2009) J Am Coll Cardiol , vol.54 , pp. 1787-1794
    • Lee, J.M.1    Robson, M.D.2    Yu, L.M.3
  • 56
    • 10044281651 scopus 로고    scopus 로고
    • Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    • Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7
    • (2004) Circulation , vol.110 , pp. 3512-3517
    • Taylor, A.J.1    Sullenberger, L.E.2    Lee, H.J.3
  • 57
    • 33751217682 scopus 로고    scopus 로고
    • The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3
    • Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
    • (2006) Curr Med Res Opin , vol.22 , pp. 2243-2250
    • Taylor, A.J.1    Lee, H.J.2    Sullenberger, L.E.3
  • 58
    • 0025678697 scopus 로고
    • Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up
    • Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-17
    • (1990) JAMA , vol.264 , pp. 3013-3017
    • Cashin-Hemphill, L.1    Mack, W.J.2    Pogoda, J.M.3
  • 59
    • 10044281651 scopus 로고    scopus 로고
    • Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    • Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
    • (2004) Circulation , vol.110 , pp. 3512-3517
    • Taylor, A.J.1    Sullenberger, L.E.2    Lee, H.J.3
  • 60
    • 0024363690 scopus 로고
    • Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART)
    • Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61
    • (1989) Lancet , vol.2 , pp. 757-761
    • Burr, M.L.1    Fehily, A.M.2    Gilbert, J.F.3
  • 61
    • 34248679878 scopus 로고    scopus 로고
    • Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events
    • Harris WS, Poston WC, Haddock CK. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007;193:1-10
    • (2007) Atherosclerosis , vol.193 , pp. 1-10
    • Harris, W.S.1    Poston, W.C.2    Haddock, C.K.3
  • 62
    • 85027956925 scopus 로고    scopus 로고
    • Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association
    • Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333
    • (2011) Circulation , vol.123 , pp. 2292-2333
    • Miller, M.1    Stone, N.J.2    Ballantyne, C.3
  • 63
    • 84866146620 scopus 로고    scopus 로고
    • Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline
    • Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969-89
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 2969-2989
    • Berglund, L.1    Brunzell, J.D.2    Goldberg, A.C.3
  • 64
    • 77956063072 scopus 로고    scopus 로고
    • Cardiovascular effects of marine omega-3 fatty acids
    • Saravanan P, Davidson NC, Schmidt EB, et al. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010;376:540-50
    • (2010) Lancet , vol.376 , pp. 540-550
    • Saravanan, P.1    Davidson, N.C.2    Schmidt, E.B.3
  • 65
    • 79955882606 scopus 로고    scopus 로고
    • Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: A double-blind, placebo-controlled, 3-arm study
    • Moertl D, Hammer A, Steiner S, et al. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011;161:e1-9
    • (2011) Am Heart J , vol.161 , pp. e1-e9
    • Moertl, D.1    Hammer, A.2    Steiner, S.3
  • 66
    • 61649116419 scopus 로고    scopus 로고
    • The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients
    • Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 2009;20:16-22
    • (2009) Platelets , vol.20 , pp. 16-22
    • Nomura, S.1    Inami, N.2    Shouzu, A.3
  • 67
    • 21044453770 scopus 로고    scopus 로고
    • N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: A randomized, controlled trial
    • Calò L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723-8
    • (2005) J Am Coll Cardiol , vol.45 , pp. 1723-1728
    • Calò, L.1    Bianconi, L.2    Colivicchi, F.3
  • 68
    • 0345109256 scopus 로고    scopus 로고
    • Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
    • Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico
    • Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55
    • (1999) Lancet , vol.354 , pp. 447-455
  • 69
    • 33947583493 scopus 로고    scopus 로고
    • Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis
    • Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
    • (2007) Lancet , vol.369 , pp. 1090-1098
    • Yokoyama, M.1    Origasa, H.2    Matsuzaki, M.3
  • 70
    • 84863789387 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
    • Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 2012;53:1755-66
    • (2012) J Lipid Res , vol.53 , pp. 1755-1766
    • Barter, P.J.1    Rye, K.A.2
  • 71
    • 4544230882 scopus 로고    scopus 로고
    • Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: The prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study
    • Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004;110:1418-23
    • (2004) Circulation , vol.110 , pp. 1418-1423
    • Boekholdt, S.M.1    Kuivenhoven, J.A.2    Wareham, N.J.3
  • 72
    • 79960257604 scopus 로고    scopus 로고
    • High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: A nested casecontrol study
    • Kappelle PJ, Perton F, Hillege HL, et al. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested casecontrol study. Atherosclerosis 2011;217:249-52
    • (2011) Atherosclerosis , vol.217 , pp. 249-252
    • Kappelle, P.J.1    Perton, F.2    Hillege, H.L.3
  • 73
    • 0022346576 scopus 로고
    • Deficiency of serum cholesterylester transfer activity in patients with familial hyperalphalipoproteinaemia
    • Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesterylester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985;58:175-86
    • (1985) Atherosclerosis , vol.58 , pp. 175-186
    • Koizumi, J.1    Mabuchi, H.2    Yoshimura, A.3
  • 74
    • 0025104275 scopus 로고
    • Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
    • Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8
    • (1990) N Engl J Med , vol.323 , pp. 1234-1238
    • Inazu, A.1    Brown, M.L.2    Hesler, C.B.3
  • 75
    • 34247214080 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice
    • Harder C, Lau P, Meng A, et al. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. Arterioscler Thromb Vasc Biol 2007;27:858-64
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 858-864
    • Harder, C.1    Lau, P.2    Meng, A.3
  • 76
    • 34047106220 scopus 로고    scopus 로고
    • Effect of torcetrapib on the progression of coronary atherosclerosis
    • Nissen SE, Tardif JC, Nicholls SJ, et al. ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
    • (2007) N Engl J Med , vol.356 , pp. 1304-1316
    • Nissen, S.E.1    Tardif, J.C.2    Nicholls, S.J.3
  • 77
    • 58149386896 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
    • Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506-14
    • (2008) Circulation , vol.118 , pp. 2506-2514
    • Nicholls, S.J.1    Tuzcu, E.M.2    Brennan, D.M.3
  • 79
    • 77952410983 scopus 로고    scopus 로고
    • Dalcetrapib: A review of Phase II data
    • Robinson JG. Dalcetrapib: a review of Phase II data. Expert Opin Investig Drugs 2010;19:795-805
    • (2010) Expert Opin Investig Drugs , vol.19 , pp. 795-805
    • Robinson, J.G.1
  • 80
    • 69549103369 scopus 로고    scopus 로고
    • Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis
    • Masson D. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis. Curr Opin Investig Drugs 2009;10:980-7
    • (2009) Curr Opin Investig Drugs , vol.10 , pp. 980-987
    • Masson, D.1
  • 82
    • 78549235583 scopus 로고    scopus 로고
    • Safety of anacetrapib in patients with or at high risk for coronary heart disease
    • Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
    • (2010) N Engl J Med , vol.363 , pp. 2406-2415
    • Cannon, C.P.1    Shah, S.2    Dansky, H.M.3
  • 83
    • 81255125373 scopus 로고    scopus 로고
    • Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial
    • Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109
    • (2011) JAMA , vol.306 , pp. 2099-2109
    • Nicholls, S.J.1    Brewer, H.B.2    Kastelein, J.J.3
  • 84
    • 84897889156 scopus 로고    scopus 로고
    • PCSK9: A key modulator of cardiovascular health
    • Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res 2014;114:1022-36
    • (2014) Circ Res , vol.114 , pp. 1022-1036
    • Seidah, N.G.1    Awan, Z.2    Chrétien, M.3
  • 85
    • 84925351969 scopus 로고    scopus 로고
    • Lipid lowering with PCSK9 inhibitors
    • Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014;11:563-75
    • (2014) Nat Rev Cardiol , vol.11 , pp. 563-575
    • Dadu, R.T.1    Ballantyne, C.M.2
  • 86
    • 34547108600 scopus 로고    scopus 로고
    • Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation
    • Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602-12
    • (2007) J Biol Chem , vol.282 , pp. 18602-18612
    • Zhang, D.W.1    Lagace, T.A.2    Garuti, R.3
  • 87
    • 84905865817 scopus 로고    scopus 로고
    • Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation
    • Mabuchi H, Nohara A, Noguchi T, et al. Hokuriku FH Study Group. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis 2014;236:54-61
    • (2014) Atherosclerosis , vol.236 , pp. 54-61
    • Mabuchi, H.1    Nohara, A.2    Noguchi, T.3
  • 88
    • 77953309816 scopus 로고    scopus 로고
    • PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses
    • Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010;55:2833-42
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2833-2842
    • Benn, M.1    Nordestgaard, B.G.2    Grande, P.3
  • 89
    • 34447299120 scopus 로고    scopus 로고
    • The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
    • Hooper AJ, Marais AD, Tanyanyiwa DM, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007;193:445-8
    • (2007) Atherosclerosis , vol.193 , pp. 445-448
    • Hooper, A.J.1    Marais, A.D.2    Tanyanyiwa, D.M.3
  • 90
    • 33748661502 scopus 로고    scopus 로고
    • Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
    • Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79:514-23
    • (2006) Am J Hum Genet , vol.79 , pp. 514-523
    • Zhao, Z.1    Tuakli-Wosornu, Y.2    Lagace, T.A.3
  • 91
    • 84862219022 scopus 로고    scopus 로고
    • Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
    • McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-53
    • (2012) J Am Coll Cardiol , vol.59 , pp. 2344-2353
    • McKenney, J.M.1    Koren, M.J.2    Kereiakes, D.J.3
  • 92
    • 84868689211 scopus 로고    scopus 로고
    • Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    • Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900
    • (2012) N Engl J Med , vol.367 , pp. 1891-1900
    • Roth, E.M.1    McKenney, J.M.2    Hanotin, C.3
  • 93
    • 84863494422 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial
    • Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36
    • (2012) Lancet , vol.380 , pp. 29-36
    • Stein, E.A.1    Gipe, D.2    Bergeron, J.3
  • 94
    • 84870478439 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACETIMI 57): A randomised, placebocontrolled, dose-ranging, phase 2 study
    • Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACETIMI 57): a randomised, placebocontrolled, dose-ranging, phase 2 study. Lancet 2012;380:2007-17
    • (2012) Lancet , vol.380 , pp. 2007-2017
    • Giugliano, R.P.1    Desai, N.R.2    Kohli, P.3
  • 95
    • 84870494510 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study
    • Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012;380:1995-2006
    • (2012) Lancet , vol.380 , pp. 1995-2006
    • Koren, M.J.1    Scott, R.2    Kim, J.B.3
  • 96
    • 84869220345 scopus 로고    scopus 로고
    • Low-density lipoprotein cholesterollowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
    • Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterollowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17
    • (2012) Circulation , vol.126 , pp. 2408-2417
    • Raal, F.1    Scott, R.2    Somaratne, R.3
  • 97
    • 84871326497 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial
    • Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506
    • (2012) JAMA , vol.308 , pp. 2497-2506
    • Sullivan, D.1    Olsson, A.G.2    Scott, R.3
  • 98
    • 84895548648 scopus 로고    scopus 로고
    • Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia
    • Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014;129:1022-32
    • (2014) Circulation , vol.129 , pp. 1022-1032
    • Rader, D.J.1    Kastelein, J.J.2
  • 99
    • 84892970756 scopus 로고    scopus 로고
    • Updates on apolipoprotein CIII: Fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease
    • Zheng C. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr Opin Lipidol 2014;25:35-9
    • (2014) Curr Opin Lipidol , vol.25 , pp. 35-39
    • Zheng, C.1
  • 100
    • 84878637167 scopus 로고    scopus 로고
    • Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans
    • Graham MJ, Lee RG, Bell TA III, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013;112:1479-90
    • (2013) Circ Res , vol.112 , pp. 1479-1490
    • Graham, M.J.1    Lee, R.G.2    Bell, T.A.3
  • 101
    • 45849110333 scopus 로고    scopus 로고
    • Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events
    • Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008;52:124-31
    • (2008) J Am Coll Cardiol , vol.52 , pp. 124-131
    • Suk Danik, J.1    Rifai, N.2    Buring, J.E.3
  • 102
    • 84878645607 scopus 로고    scopus 로고
    • The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease
    • Bochem AE, Kuivenhoven JA, Stroes ES. The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease. Curr Pharm Des 2013;19:3143-9
    • (2013) Curr Pharm des , vol.19 , pp. 3143-3149
    • Bochem, A.E.1    Kuivenhoven, J.A.2    Stroes, E.S.3
  • 103
    • 84892369781 scopus 로고    scopus 로고
    • New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect?
    • Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther 2013;27:559-67
    • (2013) Cardiovasc Drugs Ther , vol.27 , pp. 559-567
    • Sahebkar, A.1    Watts, G.F.2
  • 104
    • 84883619573 scopus 로고    scopus 로고
    • Future of high-density lipoprotein infusion therapies: Potential for clinical management of vascular disease
    • Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation 2013;128:1112-21
    • (2013) Circulation , vol.128 , pp. 1112-1121
    • Kingwell, B.A.1    Chapman, M.J.2
  • 105
    • 0242577955 scopus 로고    scopus 로고
    • Effect of recombinant ApoA-IMilano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial
    • Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-IMilano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
    • (2003) JAMA , vol.290 , pp. 2292-2300
    • Nissen, S.E.1    Tsunoda, T.2    Tuzcu, E.M.3
  • 106
    • 34247397359 scopus 로고    scopus 로고
    • Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial
    • Tardif JC, Grégoire J, L'Allier PL, et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-82
    • (2007) JAMA , vol.297 , pp. 1675-1682
    • Tardif, J.C.1    Grégoire, J.2    L'Allier, P.L.3
  • 107
    • 77953107241 scopus 로고    scopus 로고
    • A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome
    • Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010;55:2727-35
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2727-2735
    • Waksman, R.1    Torguson, R.2    Kent, K.M.3
  • 108
    • 84922150195 scopus 로고    scopus 로고
    • Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: A randomized trial
    • Epub ahead of print
    • Tardif JC, Ballantyne CM, Barter P, et al. for the Can Hdl Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 2014. [Epub ahead of print]
    • (2014) Eur Heart J
    • Tardif, J.C.1    Ballantyne, C.M.2    Barter, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.